학술논문
Zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated MSS/MSI-low metastatic colorectal cancer (mCRC): The randomized phase 3 STELLAR-303 study.
Document Type
Article
Source
Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, pTPS229-TPS229, 235p
Subject
Language
ISSN
0732183X